Crossmark

Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors

Crossref DOI link: https://doi.org/10.1007/s11523-016-0449-2

Published Online: 2016-07-25

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mita, Monica M.

Nemunaitis, John

Grilley-Olson, Juneko

El-Rayes, Bassil

Bekaii-Saab, Tanios

Harvey, R. Donald

Marshall, John

Zhang, Xiaoping

Strout, Vincent
Funding

Funding for this research was provided by:

Kyowa Kirin Development
License Information

License valid from 2016-07-25